These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31083749)

  • 1. Real-life data on improvement of survival after perioperative chemotherapy versus surgery alone on resectable adenocarcinoma of the stomach - a single-center study.
    Kuhnle PJ; Israel KF; Menges M
    Z Gastroenterol; 2019 May; 57(5):606-610. PubMed ID: 31083749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    Cunningham D; Allum WH; Stenning SP; Thompson JN; Van de Velde CJ; Nicolson M; Scarffe JH; Lofts FJ; Falk SJ; Iveson TJ; Smith DB; Langley RE; Verma M; Weeden S; Chua YJ; MAGIC Trial Participants
    N Engl J Med; 2006 Jul; 355(1):11-20. PubMed ID: 16822992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
    Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice.
    Chua YJ; Cunningham D
    Ann Surg Oncol; 2007 Oct; 14(10):2687-90. PubMed ID: 17653804
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival.
    Runkel M; Verst R; Spiegelberg J; Fichtner-Feigl S; Hoeppner J; Glatz T
    BMC Surg; 2021 Jan; 21(1):35. PubMed ID: 33435947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
    Sisic L; Crnovrsanin N; Nienhueser H; Jung JO; Schiefer S; Haag GM; Bruckner T; Schneider M; Müller-Stich BP; Büchler MW; Schmidt T
    Langenbecks Arch Surg; 2023 Feb; 408(1):81. PubMed ID: 36763220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
    BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative chemotherapy in gastroesophageal cancer. A retrospective monocenter evaluation of 42 cases.
    Brehler AC; Hartmann W; Wiebe S; Kerkhoff A; Schliemann C; Palmes D; Senninger N; Lenze F; Ullerich H; Berdel WE; Kessler T
    PLoS One; 2015; 10(4):e0122974. PubMed ID: 25855972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of perioperative FLOT compared to ECX/EOX chemotherapy regimens in resectable esophagogastric adenocarcinomas: an analysis of real-world data.
    Egebjerg K; Andersen TS; Bæksgaard L; Garbyal R; Siemsen M; Achiam M; Mau-Sørensen PM
    Acta Oncol; 2024 May; 63():322-329. PubMed ID: 38745482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
    Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
    Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?
    Briasoulis E; Fatouros M; Roukos DH
    Ann Surg Oncol; 2007 Oct; 14(10):2691-5. PubMed ID: 17653806
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction.
    Mingol F; Gallego J; Orduña A; Martinez-Blasco A; Sola-Vera J; Moya P; Morcillo MA; Ruiz JA; Calpena R; Lacueva FJ
    BMC Surg; 2015 May; 15():66. PubMed ID: 25997454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.
    Götze TO; Piso P; Lorenzen S; Bankstahl US; Pauligk C; Elshafei M; Amato G; Reim D; Bechstein WO; Königsrainer A; Mönig SP; Rau B; Schwarzbach M; Al-Batran SE
    BMC Cancer; 2021 Oct; 21(1):1158. PubMed ID: 34715810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative Chemotherapy in Elderly Patients with Locally Advanced Adenocarcinoma of the Stomach and the Esophagogastric Junction: A Retrospective Cohort Analysis of Toxicity and Efficacy at the National Center for Tumor Diseases, Heidelberg.
    Haag GM; Byl A; Jäger D; Berger AK
    Oncology; 2017; 92(5):291-298. PubMed ID: 28249280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery.
    Mongan AM; Kalachand R; King S; O'Farrell NJ; Power D; Ravi N; Muldoon C; O'Byrne K; Reynolds JV
    Ir J Med Sci; 2015 Jun; 184(2):417-23. PubMed ID: 24879337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study.
    Papaxoinis G; Kamposioras K; Weaver JMJ; Kordatou Z; Stamatopoulou S; Germetaki T; Nasralla M; Owen-Holt V; Anthoney A; Mansoor W
    J Gastrointest Surg; 2019 Sep; 23(9):1729-1741. PubMed ID: 30671799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.